Previous 10 | Next 10 |
Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 months to further elucidate safety and efficacy. The combination of high clinical f...
Pfizer has been working on New Pfizer for almost a decade. The spin offs of Consumer Health and Upjohn appear to be the last steps. Continuation of the policy of dividend growth is a stated priority. Biopharma led by scientific pipeline innovation is expected to generate $15 ...
Cellectis (CLLS) announces that the FDA has lifted the clinical hold on the Phase 1 MELANI-01 trial evaluating the UCARTCS1 product candidate for the treatment of patients with relapsed or refractory multiple myeloma ((MM)). Cellectis worked closely with the FDA to address the agency’s...
NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the U.S. Food and Drug Administration (FDA) has lift...
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Kyung Nam-Wortman a...
Cellectis S.A. (CLLS) Q3 2020 Earnings Conference Call November 6, 2020 8:00 AM ET Company Participants Simon Harnest – Senior Vice President, Corporate Strategy and Finance André Choulika – Chief Executive Officer Carrie Brownstein – Chief Medical Officer Eric Dutan...
Image source: The Motley Fool. Cellectis SA (NASDAQ: CLLS) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Cellectis SA (CLLS) Q3 2020 Earnings Call Transcript
Cellectis (CLLS): Q3 GAAP EPS of -$0.71 misses by $0.10.Revenue of $9.24M (-9.5% Y/Y) misses by $4.4M.Press Release For further details see: Cellectis EPS misses by $0.10, misses on revenue
Sponsored program at ASH 2020 – O ral p resentation of i nitial d ata for BALLI-01 c linical t rial e valuating UCART22 p roduct c andidate in a dult p atients with R/R B- c el...
Thinly traded small cap Cellectis S.A. ([[CLLS]] +4.2%) perks up on modest volume in reaction to preliminary data from a dose-escalation Phase 1 clinical trial, BALLI-01, evaluating cell therapy UCART22 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). The result...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...